Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets abnormal tyrosine‑kinase signaling in specific hematologic and solid‑tumor diseases.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by blocking KIT signaling. - Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control by suppressing BCR‑ABL activity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the hands and feet. - Muscle cramps: transient discomfort in limbs. - Fatigue: generalized tiredness. - Diarrhea: loose stools, usually self‑limiting. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced cardiac output. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemorrhage: unusual bleeding or bruising.

Patients should be monitored closely for safety concerns before and during therapy.

- Blood counts: monitor complete blood count regularly. - Liver function: assess hepatic enzymes periodically. - Cardiac assessment: evaluate heart function in patients with pre‑existing cardiac disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Renal impairment: adjust dosing in severe renal dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, tacrolimus): may require dose adjustments. - QT‑prolonging agents (e.g., quinidine, sotalol): monitor cardiac rhythm. - Vaccines (live attenuated): assess timing relative to therapy.